Robert Blaustein - 12 Aug 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Reporting relationship: Chief Development Officer
Issuer ticker: EWTX
Reported as of: 12 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Aug 2025, 19:44:14 UTC
Prior SEC filing: 23 Jan 2025
Source filing: View source filing
Reporting owner signature: John R. Moore, by POA from Robert Blaustein

Key filing fact

Robert Blaustein filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 14 Aug 2025.

Key facts

This page summarizes Robert Blaustein's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 Aug 2025, 19:44.

Change

Previous filing in this sequence was filed on 23 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002053149 Primary reporting owner

Blaustein Robert

Relationship: Chief Development Officer
Address: 1715 38TH STREET, BOULDER
Signature: John R. Moore, by POA from Robert Blaustein
Signature date: 14 Aug 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EWTX transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +17,500
Change %
Price: $0.000000
Shares after: 17,500
Date: 12 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,500
Exercise price: $0.000000
Footnotes: F1

EWTX transaction Derivative

Stock Options (Right to buy)

Award

Transaction value: $0
Shares: +105,000
Change %
Price: $0.000000
Shares after: 105,000
Date: 12 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 105,000
Exercise price: $13.39
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

Footnote F2

1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.